THE ROLE OF GENOMIC SCREENING IN TRANSFORMING PUBLIC HEALTH Understanding ethical, legal & social impacts of genomic screening
With
Dr Jane Tiller, Ethical, Legal & Social Adviser,
Public Health Genomics, Monash University
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | July 2025
Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.
Jane also focusses on identifying and addressing the ethical, legal and social barriers to public acceptability and uptake of genetic screening. She co-founded the Australian Genetic Non-Discrimination Working Group, and led a project from 2020-2023 about genetic discrimination in life insurance. Jane led significant advocacy efforts towards translating her research findings into real world policy change. She was instrumental in the Government’s 2024 announcement that it will legislate a total ban on the use of genetic results in life insurance underwriting. Jane’s work has been recognised through a number of competitive awards, including recently the prestigious 2024 Research Australia Advocacy Award.
Source: Supplied
-
Cardiovascular Disease Risk Guidance and Calculator get long overdue update
Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.
-
Priming Australia for social prescribing
Social prescribing provides support in various areas of people’s lives, leading to increased confidence, improved navigation of systems, and enhanced friendships and trust in healthcare, while communities should be designed in an age-friendly way to prevent isolation.
In Part 1 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people advocating for social prescribing in Australia
-
Impact of genetic pathologist role across medicine
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
